Francine FangFounding Partner at 3E Bioventures
Dr. Francine Fang is founding partner of 3E Bioventures. She focuses on investment mainly in IT/BT cross-disciplinary innovation of medical device and diagnostics. She led the investment transactions of Eyebright (688050.SH), Cytek, Genotix, Wenxin tech and Lyratone.
Prior to 3E Bioventures, Francine worked at Fidelity Growth Partners Asia (FGPA) as venture partner. Prior to FGPA, Francine was healthcare fund partner in Tuspark Venture. She led and was involved in various investment deals covering therapeutic drug, IVD and device.
From 1998 to 2007, Francine worked at Clontech and BD Biosciences as a group leader in research and development for near 10 years in US. Francine has Ph.D. degree in Physiology and Neuroscience at Rutgers University and M.D. degree in Medicine at Capital Institute of Medicine in Beijing China.US